Bivalirudin dosing during prolonged intermittent renal replacement therapy: a case report
Related Experiment Video
Updated: Dec 5, 2025

Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
1Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC, USA. bohm@musc.edu.
Abstract:
As patients transition between dialysis modalities, and from the intra- to the inter-dialytic period, medications with a narrow therapeutic index that are cleared in dialysis may require dose adjustments and close monitoring. Three cases of patients receiving bivalirudin while converting from continuous to prolonged intermittent renal replacement therapy are reported. Details provided include flow rates and ultrafiltrate volume. In these cases, it appears pre-emptive dose adjustments may be unwarranted, and clinicians should be aware of potential rebound after cessation of dialysis.
More Related Videos
09:02A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
Related Concept Videos
Continuous Renal Replacement Therapy
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Venous Thrombosis III: Interprofessional Care
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant